D-0348-2025 Class II Ongoing

Recalled by Glenmark Pharmaceuticals Inc., USA — Mahwah, NJ

FDA drug recall D-0348-2025 was initiated by Glenmark Pharmaceuticals Inc., USA on Mar 13, 2025 and is designated Class II. Reason for recall: CGMP Deviations The recall status is ongoing.

Recall details

Product Type
Drugs
Report Date
Apr 16, 2025
Initiation Date
Mar 13, 2025
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Cetirizine Hydrochloride Tablets, USP, 10mg, 365-count packs, Rx Only, Manufactured for: Glenmark Therapeutics Inc., Distributed by: Amazon. NDC# 72657-129-35

Reason for recall

CGMP Deviations

Distribution pattern

U.S. Nationwide

Code information

Lot # 17231980, ep.. date Aug-25 Amazon 17232044, ep.. date Aug-25 Walmart 17241436, ep.. date Jul-26 Amazon 17241437, ep.. date Jul-26 Amazon 17241455, ep.. date Jul-26 Amazon 17241456, ep.. date Aug-26 Amazon 17241457, ep.. date Aug-26 Amazon 17241892, ep.. date Oct-26 Amazon 17241893, ep.. date Oct-26 Amazon

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0348-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0348-2025. Report a data issue: hello@regdatalab.com.